Australian (ASX) Stock Market Forum

SLA - Solagran Limited

Jump to new
It sounds very interesting pacer.

Looks like things are already starting to happen for SLA earlier than we expected.

Lucky I got in at 25 and 36.

I had a bid in at 36 yesterday and I missed out because the price went nuts!!

Any thoughts on what will happen tomorrow?

Surely the price will come off a little considering the strong rise today .........
 
I hope it comes off this week, but I doubt it.......


I think most people missed the part in the latest newsletter about the injectable form of Ropren the company is working on. Don't underestimate what this means for sales and profits as it will require far less ropren per course thus allowing the drug to achieve higher penetration levels from the beginning.

Does anyone know what % less ropren will need to be administered by injection?

If say only 1/3 is needed then $1000 per dose would give us the $18 mill per 24 kilos still, or they could decide to charge $2000 per dose, injected, and make that $36 mill, while still giving a 30% dicount on the $3000 initialy priced......so it all depends on what % of ropren is necessary to achieve the same result.....
maybe they will even come out with other delivery systems......eg slow release(under the skin), patches, sprays, ect....

Interesting when you think about it....

PS....my liver could do with about a kilo injected into it after last night ....lol......:)
 
Where are all the holders, this is gonna be huge me thinks.....
Looks like it is breaking out....when it hits the market it will be worth mega bucks...bring on the SOLA -COLA....:D


Got some more at 47c the day before the news....more news coming........

surely has to the best BIO-stock I ever bought.....
 
Pacer, I wish I'd known a few months ago that everything you touched would turn to gold. - Pacer the Midas Touch. :banghead: :)
 
CanOz said:
How do i read that without being a member?

If your going to ramp Pacer, at least give us your password! :D

Cheers,
Click to expand...


It's free to log in...just make your own account........sorry......this is an awesome blurb.....just apply and it's free


Melbourne based biotech Solagran Limited (ASX: SLA) has announced an important extension to the successful neurodegenerative disorders trials it is conducting in both Melbourne and St Petersburg Since listing in August 2003, Solagran has been commercialising a range of natural pharmaceuticals known as Bioeffectives. These multiple molecule substances each have many applications but few if any side effects. They are obtained from green conifer needles using a patented extraction process. Solagran acquired the underlying intellectual property from the St Petersburg Forest Technical Academy in the late 1990s in a commercial arrangement that involved key scientists acquiring a substantial shareholding in the company. Further development enabled the company to acquire a comprehensive new global technology patent not long after it listed a little over three years ago. Solagran is now poised to lead world in production of this new category of pharmaceuticals, which includes a particularly valuable class of substance known as polyprenols. Solagran’s Bioeffective R is comprised entirely of polyprenols.

In 2005, Solagran conducted successful trials at St Petersburg’s Skvortsova-Stepanova Psychiatric Hospital using Ropren (the finished dose form of Bioeffective R) to treat Alzheimer’s patients. The results demonstrated that administration of Ropren for a four month period led to an average 38 percent improvement in cognitive function among patients who had been suffering from Alzheimer’s for between six months and four years. 44 percent of patients experienced an improvement in cognitive function of 50 percent or more. 24 percent experienced an improvement of 100 percent or more. The trials also demonstrated that treatment with Ropren resulted in the elimination of most other Alzheimer’s symptoms, including depression. It also led to a normalisation of the activity of key enzymes in blood plasma, which in the opinion of Solagran Executive Chairman Dr Vagif Soultanov, provides evidence of a link between liver degeneration and the incidence of neurodegenerative disorders like Alzheimer’s – something he has hypothesized for many years. (This might explain the relatively high incidence of these disorders in western society where liver degeneration arising from inappropriate diet, alcohol abuse, and the widespread consumption of prescription and over the counter drugs, is also relatively high.)

Following this and other studies in St Petersburg, further trials to understand Ropren’s potential were undertaken in Melbourne by Swinburne University’s Brain Sciences Institute on 100 healthy volunteers aged 60 to 85 years. The positive preliminary results of these trials were announced last November. They indicated that treatment with Ropren led to:

1. A 15 percent or more improvement in memory function and speed of recall. This was a significant uplift for healthy volunteers in this age group.
2. Significant improvements in liver function (particularly in its protein synthesising function) together with other blood biochemical indices.
3. A marked reduction in Low Density Lipoproteins (LDL) combined with an equally marked increase in High Density Lipoproteins (HDL). This has major implications for the potential use of Ropren as a treatment to normalise cholesterol levels.
4. No adverse outcomes or side effects.

The final report from the Swinburne University study is to be received by Solagran in mid February 2007.

While the Swinburne trials were under way, a further trial involving the use of Ropren to treat critically ill heroin-addicted chronic alcoholics was completed at the Skvortsova-Stepanova Hospital. While not yet released for reasons related to ongoing intellectual property protection work, Solagran says the findings from the trial are significant. Some feedback from the research team was announced in October 2006 – including a firm policy decision by the hospital to incorporate Ropren into its clinical practice for the treatment of drug induced psychoses and other conditions associated with alcohol and drug addiction.

As a direct result of the clinical outcomes achieved with that trial, Solagran has now reached an agreement with the Head Physician and scientific medical team of the Skvortsova-Stepanova Hospital to conduct a virtually identical trial using another of its family of 15 Bioeffectives – in this case Bioeffective A. Bioeffective A is already listed with the TGA in Australia, and is now the subject of an NDI application with the Food and Drug Administration in the USA.

Both Solagran and the research team at the Skvortsova-Stepanova hospital believe that use of Bioeffective A, either in conjunction with or as and adjunct to treatment with Ropren, could have the potential to produce a number of positive physiological and neurological clinical outcomes for alcoholics and heroin addicts. This could lead to a treatment regime involving a relatively short treatment with Ropren combined with longer term treatment with lower cost Bioeffective A.

The new St Petersburg trial involves 50 patients aged 18 to 60 years. It has already commenced and the final report will be delivered by June 1 this year.

While the focus of much of the recent research with Ropren has been focused on its use in the prevention and treatment of neurodegenerative disorders, Ropren has a wide range of applications. It has also been shown to enhance immune system response and has already completed clinical trials as a safe and highly effective treatment for chronic liver disease. It is expected to be listed in the Russian Pharmacopoeia for this application in March 2007. There are 10 million Russians with chronic liver disease so the initial demand is expected to be significant.

Solagran is currently gearing up for full scale commercial production. Once this production capacity is up and running, regulations will permit Solagran to directly supply three month courses of the drug for personal use to people in many countries throughout the world.

A Director of Solagran, Mr Peter Stedwell, told Australian Investor that the Board believed its international trials and market development strategy would soon generate significant revenues. “The entry of Ropren into the Russian Pharmacopoeia will be quite an achievement just four years after listing on the ASX. The trial results suggest that Ropren could be a leading product in a number of large international pharmaceutical markets in the relatively near future” Stedwell said.

The Solagran website is at www.solagran.com

e
 
Where are you now Caliente.....?

Sorry it took so long to find them damn indepedant reports.......:p:


How many do you hold?......;)
 
Solagran seems to be a good stock. but they are not gaining any profit. So look at Solco, we gpt the turnaround. We had our first profit with 0,37 Mio $ in the first quarter. The stock price is still very cheap, still!!
There is potential. DOn ´t forget Solco!! Good luck with Solagran!!
 
hey pacer! little late for me to jump on board :p

Thought they were expensive in the 30's, now they're rocketing away.

So the answer I'm afraid is none =(
 
Another good day for holders......
Sunboy, SLA has 24 kilos of BIO-R ready for sale at around $18 mill, which will be sold as soon as the Russians gain approval to do so in March.

Market cap is $37 mill acording to etrade, do the math on all the other products aswell and I think this is still a cheapie....

As for them not making any profit, I think you should reaserch before you make those statements.....Bio-b is on the shelves and will be making a tidy profit right now, the sauna market has taken it on board with open arms.

Other product lines are on thier way, they intend to supply thier product to other companies to manufacure evreything from toothpaste to sunscreen, with the solagran badge shing brightly.

Bio-R is gonna be huge, but the others will only add to the bottom line.

Call it ramping if you like, but all is fact from what I have seen.
 
Hey pacer,

Market cap is MUCH higher than $37m, but that is not necessarily a bad thing.

Etrade/comsec etc never include options and escrowed shares.

The total shares on issue (including ordinary fully paids, listed and unlisted options and escrowed shares) are around 200m.

At 60 cents, this gives SLA a fully diluted market cap of $120m.
 
Sorry davepan....etrade sux....still 18 mill worth of bio -R on hand and more to be made with the sibex deal, and all the other 15 Bio effectives, still makes this cheap IMO.

Regular news makes this a good one to hold, less bourbon and I wont need to hold...lol........:eek:
 
Look for final Swinborne results next week, and more on the way.
Boardroom Radio had another interview yesterday......

I thought we might get a retracement on this one but it appears to be overcoming the traders with actual investors piling in....great volume again yesterday, even though it only finished up 1c and we have a similar start to today, up 6c/10%.

I don't intend selling this one except in dire circumstances, it's just got too much going for it, no need for me to ramp it......the results speak for themselves......and the SP reflecting the potential, up 200% in 4 months.

DYOR......and it's well worth the time doing it here.
 
Yo Pacer,

After reading your posts and doing my own...I bought in rather hesitantly yesterday worrying it had topped...up 15% already! Thanks mate, good advice/info I should have taken notice of earlier.

Not too late yet it seems, if this company is now putting products on the shelf then why should the growth stop except for the odd breather?
 
moses said:
Yo Pacer,

After reading your posts and doing my own...I bought in rather hesitantly yesterday worrying it had topped...up 15% already! Thanks mate, good advice/info I should have taken notice of earlier.

Not too late yet it seems, if this company is now putting products on the shelf then why should the growth stop except for the odd breather?
Click to expand...

A bit of selling pressure creeping in now. Can't blame the sellers really, tempting to take a profit after that run.

Cheers,
 
pacer......been wasting my time waiting on NWR news when SLA has been charging up. jumped on yesterday finally. enjoyed reading your posts on SLA. cheers.
 

Similar threads

ducati916
September DDD
2 3 4
Replies
66
Views
9K
qldfrog
qldfrog
farmerge
Being absent
Replies
18
Views
2K
IFocus
IFocus
sptrawler
Competency and trying to maintain standards
2
Replies
27
Views
3K
sptrawler
sptrawler
ducati916
November DDD
2 3
Replies
46
Views
3K
ducati916
ducati916
mullokintyre
The Law of Unintended Consequences
2
Replies
23
Views
2K
basilio
basilio
Top